Shanghai Hengrui Pharmaceutical Co., Ltd.
Clinical trials sponsored by Shanghai Hengrui Pharmaceutical Co., Ltd., explained in plain language.
A Chinese pharmaceutical subsidiary of Hengrui, developing drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug cocktail aims to shrink Hard-to-Treat lung tumors Results expected Oct 2026 (estimated)
- New drug combo aims to wipe out lung cancer before surgery Results expected Oct 2026 (estimated)
- Experimental injection SHR-7787 put to the test against advanced solid tumors Results expected Dec 2026 (estimated)
- New asthma drug shows promise in reducing severe attacks Results expected Dec 2026 (estimated)
- New drug combo HRS8807 and SHR6390 targets tough breast cancer Results expected Dec 2026 (estimated)
-
New asthma drug shows promise in reducing severe attacks
Disease control OngoingThis study tests a new medicine called SHR-1905 for people with severe asthma that is not well controlled by current treatments. About 260 adults will receive either the drug or a placebo to see if it reduces asthma attacks and improves breathing and quality of life. The goal is …
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo HRS8807 and SHR6390 targets tough breast cancer
Disease control OngoingThis early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC